Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Seikagaku Corporation (4548.T)
Tokyo, JP
Headquartered in Tokyo, Japan, Seikagaku Corporation, established in 1947, specializes in the global development, manufacturing, and distribution of pharmaceuticals and medical devices, with a core focus on glycoconjugates. The company, which was formerly known as K.K. Seikagaku Kenkyusho until its name change in 1962, operates through two primary segments: Pharmaceuticals and LAL. Its product portfolio encompasses a range of therapeutic and surgical solutions. For joint health, Seikagaku provides intra-articular injections like ARTZ, ARTZ Dispo, VISCO-3, and SUPARTZ FX, designed to enhance joint function. The company also supplies ophthalmic surgical aids such as OPEGAN, OPEGAN Hi, and SHELLGAN, alongside MucoUp for endoscopic mucosal resection. Other notable offerings include Gel-One, a cross-linked hyaluronate hydrogel addressing knee osteoarthritis, and HERNICORE for lumbar disc herniation. Beyond finished products, Seikagaku is a supplier of bulk materials, specifically sodium hyaluronate and sodium chondroitin sulfate, which find application in various pharmaceutical and cosmetic formulations. Furthermore, the company develops and markets specialized endotoxin-detecting reagents, including Pyrochrome, ENDOSPECY, and TOXICOLOR, which are crucial for quality assurance in injectable pharmaceuticals, biological products, medical devices, manufacturing operations, and dialysate water quality. Its offerings also extend to oral care, featuring the KINUSUI Spray mouthwash. Seikagaku maintains a robust development pipeline, with promising candidates such as SI-6603 for lumbar disc herniation, SI-614 (a modified hyaluronate for dry eyes), SI-613 for osteoarthritis, SI-613-ETP targeting enthesopathy, and SI-449, a powdered adhesion barrier.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.27% | +5.19% | +1.63% | +6.08% | +10.29% | +4.75% | +14.16% | -4.46% | -29.71% | -51.14% | +31.84% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Devices: +11.2%-6.9% Q1'26: +8.8% (vs Q1'25)
-
EPS growth Medical - Devices: +28.5%+21.3% Q1'26: +118.9% (vs Q1'25)
-
FCF margin FCF growth · Medical - Devices: +30.9%-11.6% Q1'26: +0.0% (vs Q1'25)
-
EBIT margin Medical - Devices: +6.2%-1.6% Q1'26: -0.3% (vs Q1'25)
-
ROIC Medical - Devices: +3.3%-1.0% Q1'26: -0.2% (vs Q1'25)
-
Share dilution Medical - Devices: 0.0%+0.0% Q1'26: +0.0% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Devices: -0.35×0.24× ★ Q1'26: 0.16× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Mar 2015 actual |
Mar 2016 actual |
Mar 2017 actual |
Mar 2018 actual |
Mar 2019 actual |
Mar 2020 actual |
Mar 2021 actual |
Mar 2022 actual |
Mar 2023 actual |
Mar 2024 actual |
Mar 2025 actual |
Mar 2026 1 Rev. Ana. 1 EPS Ana. |
Mar 2027 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
29.52B
est: 29.40B (+0.4%)
|
30.96B
est: 31.40B (-1.4%)
|
29.59B
est: 29.50B (+0.3%)
|
30.18B
est: 30.50B (-1.1%)
|
28.38B
est: 28.35B (+0.1%)
|
28.64B
est: 29.90B (-4.2%)
|
27.66B
est: 27.75B (-0.3%)
|
34.85B
est: 34.50B (+1.0%)
|
33.46B
est: 33.50B (-0.1%)
|
36.21B
est: 36.10B (+0.3%)
|
39.37B
est: 34.50B (+14.1%)
|
36.20B
36.20B – 36.20B
+4.9% YoY
|
36.50B
36.50B – 36.50B
+0.8% YoY
|
| EBITDA |
4.99B
est: 3.81B (+31.0%)
|
5.34B
est: 4.07B (+31.0%)
|
5.43B
est: 3.83B (+41.9%)
|
8.28B
est: 3.96B (+109.3%)
|
3.88B
est: 3.68B (+5.5%)
|
-7.65B
est: 3.88B (-297.3%)
|
3.85B
est: 3.60B (+6.9%)
|
6.46B
est: 4.47B (+44.3%)
|
4.40B
est: 4.35B (+1.3%)
|
3.36B
est: 4.68B (-28.3%)
|
3.93B
est: 4.47B (-12.1%)
|
4.70B
4.70B – 4.70B
+4.9% YoY
|
4.73B
4.73B – 4.73B
+0.8% YoY
|
| EBIT |
4.03B
est: 2.66B (+51.2%)
|
3.54B
est: 2.84B (+24.3%)
|
2.51B
est: 2.67B (-6.1%)
|
5.35B
est: 2.76B (+93.8%)
|
978.00M
est: 2.57B (-61.9%)
|
-9.53B
est: 2.71B (-451.7%)
|
3.04B
est: 2.51B (+20.9%)
|
5.41B
est: 3.13B (+73.0%)
|
3.07B
est: 3.03B (+1.3%)
|
1.70B
est: 3.27B (-48.2%)
|
1.94B
est: 3.13B (-38.0%)
|
3.28B
3.28B – 3.28B
+4.9% YoY
|
3.31B
3.31B – 3.31B
+0.8% YoY
|
| Net Income |
3.65B
est: 3.62B (+0.8%)
|
2.58B
est: 3.07B (-16.1%)
|
1.79B
est: 2.12B (-15.8%)
|
3.92B
est: 3.18B (+23.3%)
|
2.24B
est: 2.13B (+5.4%)
|
-10.84B
est: -9.68B (-12.0%)
|
4.26B
est: 4.16B (+2.5%)
|
3.73B
est: 4.37B (-14.5%)
|
2.24B
est: 2.60B (-14.1%)
|
2.19B
est: 2.60B (-16.0%)
|
1.21B
est: 1.76B (-31.1%)
|
2.70B
2.70B – 2.70B
+53.3% YoY
|
2.83B
2.83B – 2.83B
+4.8% YoY
|
| SGA |
1.74B
est: 7.01B (-75.2%)
|
1.76B
est: 7.48B (-76.5%)
|
1.68B
est: 7.03B (-76.1%)
|
1.66B
est: 7.27B (-77.2%)
|
1.45B
est: 6.76B (-78.6%)
|
1.31B
est: 7.13B (-81.6%)
|
6.81B
est: 6.61B (+3.0%)
|
7.03B
est: 8.22B (-14.5%)
|
7.96B
est: 7.98B (-0.3%)
|
8.96B
est: 8.60B (+4.1%)
|
10.18B
est: 8.22B (+23.8%)
|
8.63B
8.63B – 8.63B
+4.9% YoY
|
8.70B
8.70B – 8.70B
+0.8% YoY
|
| EPS |
64.27
est: 66.35 (-3.1%)
|
45.39
est: 56.30 (-19.4%)
|
31.55
est: 38.90 (-18.9%)
|
69.29
est: 58.30 (+18.9%)
|
39.75
est: 39.00 (+1.9%)
|
-192.14
est: -177.30 (-8.4%)
|
75.53
est: 76.20 (-0.9%)
|
66.31
est: 80.00 (-17.1%)
|
40.48
est: 47.70 (-15.1%)
|
40.07
est: 47.70 (-16.0%)
|
22.25
est: 32.30 (-31.1%)
|
49.50
49.50 – 49.50
+53.3% YoY
|
51.90
51.90 – 51.90
+4.8% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-12 | B- | 3/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 5/5 |
| 2026-05-11 | B- | 3/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 5/5 |
| 2026-05-08 | B- | 3/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 5/5 |
| 2026-05-07 | B- | 3/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 5/5 |
| 2026-05-01 | B- | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-04-30 | B- | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-04-28 | B- | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-04-27 | B- | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-04-24 | B- | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-04-23 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-22 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-21 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-20 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-17 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-16 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | State Street SPDR S&P International Small Cap ETF GWX | 0.01% | 113.7K | 0.40% |
| 2 | Avantis International Small Cap Equity ETF AVDS | 0.00% | 15.3K | 0.30% |
| 3 | Vanguard FTSE All-World ex-US Small-Cap ETF VSS | 0.00% | 590.8K | 0.06% |
| 4 | Schwab International Small-Cap Equity ETF SCHC | 0.00% | 202.4K | 0.06% |
| 5 | iShares Core TOPIX ETF 1475.T | 0.00% | 431.0K | 0.05% |
| 6 | Vanguard ESG International Stock ETF VSGX | 0.00% | 102.8K | 0.10% |
| 7 | Vanguard FTSE Developed All Cap ex North America Index ETF (CAD-hedged) VI.TO | 0.00% | 8.3K | 0.22% |
| 8 | Vanguard FTSE Developed All Cap ex North America Index ETF VIU.TO | 0.00% | 96.3K | 0.23% |
| 9 | Vanguard FTSE Developed Asia Pacific All Cap Index ETF VA.TO | 0.00% | 2.0K | 0.22% |
| 10 | Vanguard FTSE Developed All Cap ex U.S. Index ETF VDU.TO | 0.00% | 3.2K | 0.22% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Kazushi Takeda | Senior Executive Officer, Executive Vice President of F&A and Corporate Staff | — | — |
| Kenji Mizutani | President, Chief Executive Officer & Representative Director | — | male |
| Masayuki Ito | Executive Vice President & Head of Production | — | — |
| Ryoji Tomokiyo | Executive Vice President of Business Development & Marketing | — | — |
| Toshiyuki Okada | Managing Executive Officer & Director | — | male |
| Yosuke Funakoshi | Senior Executive Officer, GM of Research & Development and Director | — | male |
| Yuji Shimojima | Executive Vice President of Overseas Subsidiaries & Medical Science | — | — |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 4548.T
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
